Profusa to Present Late-Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025: Evaluating Lumee Oxygen Tissue Monitoring Platform in Peripheral Artery Disease Patients.

Profusa, a digital health company, will present an update on its U.S.-based clinical trial evaluating its Lumee Oxygen tissue monitoring platform in peripheral artery disease patients at Paris Vascular Insights 2025. The platform uses transcutaneous partial pressure of oxygen (tcpO2) to continuously monitor tissue oxygen dynamics. Profusa's CEO, Ben Hwang, stated that the company is excited to present the update at the late-breaking session.